Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Insmed's Treprostinil Palmitil?
Treprostinil Palmitil is a small molecule commercialized by Insmed, with a leading Phase III program in Pulmonary Arterial Hypertension. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Insmed's Treprostinil Palmitil?
Treprostinil Palmitil is a small molecule commercialized by Insmed, with a leading Phase III program in Interstitial Lung Diseases (Diffuse...